Is this email not displaying correctly? View it in your browser.
 
Newswise - News for JournalistsNewswise - pix
Newswise Special Wire
Tuesday, June 2, 2020

Public edition | newswise.com

Newswise Cancer Research Wire for 02-Jun-2020
 

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.


Cancer Research


Discovery in Acute Myeloid Leukemia Could Provide Novel Pathway for New Treatments

Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a dis...

– Mount Sinai Health System

Cell Reports, Jun-2020

Embargo expired on 02-Jun-2020 at 11:00 ET


Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoin...

– Dana-Farber Cancer Institute

Nature Medicine, May 29, 2020; ASCO Virtual Scientific Program, May-2020; P50-CA101942-12; W81XWH-18-1-0480; NCI-1RO1CA155010 ; NIH/NCI U24 CA224331

Embargo expired on 29-May-2020 at 11:00 ET


Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with...

– Yale Cancer Center

ASCO 2020

Embargo expired on 28-May-2020 at 17:00 ET


Researchers Identify a Moving Target in Small Cell Lung Tumors

About 15 percent of lung cancers are classified as small cell lung cancer. Recent studies have indicated that four major subtypes of small cell lung cancer exist, yet approaches to tailor treatment of these subtypes have not yet become standard of ca...

– Huntsman Cancer Institute at the University of Utah

Cancer Cell


Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer

Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostat...

– Yale Cancer Center

ASCO 2020


Huntsman Cancer Institute Researchers Demonstrate Better Outcomes, Lower Cost in First-Ever Oncology Hospital-at-Home Evaluation

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology (ASCO) annual meeting. The...

– Huntsman Cancer Institute at the University of Utah

American Society of Clinical Oncology Annual Meeting 2020


Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targe...

– Roswell Park Comprehensive Cancer Center

American Society of Clinical Oncology (ASCO) 2020


Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at...

– University of Texas M. D. Anderson Cancer Center

2020 American Society of Clinical Oncology Annual Meeting


Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Me...

– University of Texas M. D. Anderson Cancer Center

New England Journal of Medicine; American Society of Clinical Oncology (ASCO) Annual Meeting


Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer...

– University of Texas M. D. Anderson Cancer Center

2020 American Society of Clinical Oncology Annual Meeting


Decisions to Stray From Clinical Oncology Pathways Are Often Justified, Roswell Park Analysis Shows

Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional’s decision to depart from the recommendations of these decision-support res...

– Roswell Park Comprehensive Cancer Center

ASCO 2020 Virtual


Building an International Consortium to Enhance Decision Making in Hodgkin Lymphoma

Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.

– Rutgers Cancer Institute of New Jersey

American Society for Clinical Oncology Annual Meeting


Study Shows Promise for Non-Small Cell Lung Cancer Patients Who Require New Treatment Options

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System. Early results appear promising in this phase...

– Atlantic Health System


Study finds overwhelming support for smoke-free policies among Los Angeles tenants, landlords

Half of apartment dwellers in Los Angeles report having been exposed to unwanted secondhand smoke in their homes in the last year, and 9 in 10 of them say they favor policies banning smoking from their buildings, a new study by researchers at the Fie...

– UCLA Fielding School of Public Health


Ludwig Lausanne Study Charts the Immune Landscape of Multiple Brain Cancers

A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.

– Ludwig Cancer Research

Cell, May-2020


Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer

In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for pat...

– University of Texas M. D. Anderson Cancer Center

2020 American Society of Clinical Oncology Annual Meeting


Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University...

– University of Texas M. D. Anderson Cancer Center

2020 American Society of Clinical Oncology (ASCO) Annual Meeting


At-home screening for ovarian, breast cancers is effective

At-home genetic-testing kits for breast and ovarian cancer risk are just as effective, and in some cases even more so, than the typical protocol for genetic testing, which requires repeated office visits and counseling, according to a study led by UW...

– University of Washington School of Medicine and UW Medicine

American Society of Clinical Oncology


New drug combinations help overcome resistance to immunotherapy

A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome res...

– University of California, Los Angeles (UCLA), Health Sciences

Cancer Discovery


Colorado tool, My-DST, may pick best multiple myeloma treatment

University of Colorado Cancer Center team uses liquid biopsy to predict multiple myeloma drug resistance and sensitivity.

– University of Colorado Cancer Center

Blood Advances


Atlantic Health System Leads Phase 1 Study on CPI-613® (Devimistat), First-in-Class Treatment for Pancreatic Cancer to be Presented at American Society of Clinical Oncology (ASCO) 2020

Dr. Alistar has pioneered the use of CPI-613® (devimistat), a unique first-in-class treatment for locally advanced or metastatic pancreatic cancer, in combination with two chemotherapy drugs. Devimistat uniquely targets enzymes involved in cancer c...

– Atlantic Health System

2020 American Society of Clinical Oncology (ASCO) Virtual Program


Phase III Trial Shows Avelumab an Immunotherapy Treatment for Advanced Urothelial Cancer Prolongs Overall Survival

During a plenary session of the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, findings will be presented from the global phase III JAVELIN Bladder 100 randomized study conducted by investigators from Seattle Cancer Car...

– Seattle Cancer Care Alliance


New Cancer Immunotherapy Targeting Myeloid Cells Slows Tumor Growth

Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions. Reporting in Nature Cancer...

– Perelman School of Medicine at the University of Pennsylvania

Nature Cancer 1, 507–517 (2020)


Troublemaking ‘lesion’ singled out in UV-caused skin cancer

Upon exposure to human skin, ultraviolet light from the sun almost instantly generates two types of "lesions" that damage DNA. Scientists at UW Medicine in Seattle determined which of these lesions is responsible for activating a process that may inc...

– University of Washington School of Medicine

PNAS; R01-AR049832; R01-AR067722; R21-ES019485


Urge to merge: Understanding how cells fuse

New research from UT Southwestern may help those with rare muscle diseases

– UT Southwestern Medical Center

Nature Cell Biology


Research News Tip Sheet: Story Ideas From Johns Hopkins

During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas ...

– Johns Hopkins Medicine

Journal of Clinical Oncology


Cancer Experts and Features


MSK: Cancer Isn’t Sheltering in Place

As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now – as the long-term toll of mis...

– Memorial Sloan Kettering Cancer Center


Darrigues selected for competitive postdoctoral research program at UAMS

A University of Arkansas at Little Rock doctoral student has been selected for a highly competitive postdoctoral scholarship at the University of Arkansas for Medical Sciences. Emilie Darrigues, a doctoral student in applied science with an emphasis...

– University of Arkansas at Little Rock


UT Southwestern, Children's Health recognized for care of Duchenne muscular dystrophy

A joint program of UT Southwestern Medical Center and Children’s Health has been approved as a Certified Duchenne Care Center (CDCC) by Parent Project Muscular Dystrophy (PPMD), the nation’s most comprehensive nonprofit organization focused on fi...

– UT Southwestern Medical Center


Your Cancer Care is too Important to Wait

Minimizing your exposure to COVID-19 doesn’t require sacrificing cancer care or preventive services. Rutgers Cancer Institute of New Jersey and RWJBarnabas Health are taking extra precautions to ensure that patients can continue to receive exceptio...

Expert Available

– Rutgers Cancer Institute of New Jersey


Cancer Announcements


Eighth Annual Cancer Immunotherapy Month™ in June Celebrates Progress in Treatment and Advances in Research

June is Cancer Immunotherapy Month, a 30-day awareness campaign started by the Cancer Research Institute eight years ago to educate, inform, and inspire the global community of patients, caregivers, scientists, donors, and other cancer-concerned indi...

– Cancer Research Institute


Rutgers Cancer Institute of New Jersey Chair of Radiation Oncology and Associate Vice Chancellor of Cancer Programs Receives Prestigious National Award

Bruce G. Haffty, MD, associate vice chancellor for cancer programs and chair, radiation oncology at Rutgers Cancer Institute of New Jersey has been selected as the 2020 Gold Medal Award winner by the American Society for Radiation Oncology (ASTRO), ...

– Rutgers Cancer Institute of New Jersey


Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants

Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

– Dana-Farber Cancer Institute

Tips

CUSTOMIZE YOUR FAVORITES WITH "MY READING LIST"

MY CHANNELS  |  SAVED ARTICLES  |  MY SOURCES  |  MY EXPERTS

MORE CHANNELS:
JOURNAL NEWS   |  TRENDS AND TOP STORIES   |  LOCAL NEWS  |  MEDICAL and SCIENTIFIC MEETINGS

Support
 Subscribe/Unsubscribe
 Edit My Preferences
 Comments/Suggestions
 Contact Us
 
Services
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:

 UT Southwestern Medical Center

 University of Texas M. D. Anderson Cancer Center

 University of California, Los Angeles (UCLA), Health Sciences

 Seattle Cancer Care Alliance

 The Rockefeller University Press

 UCLA Fielding School of Public Health


Subscribe / Unsubscribe
Edit my preferences

© 2020 Newswise, Inc. All Rights Reserved.

265 Turkey Sag Trail Suite 102, #110 Palmyra VA 22963 | 434-296-9417

 Contact Us